IP Library › Granted Patent US 10,308,972
Granted Patent B2
US 10,308,972 · App. 14/898,655 · Granted Jun 4, 2019

Whole-cell system for cytochrome P450 monooxygenases biocatalysis

Inventors: Adrian Gerber (Saarbrücken, DE); Frank Hannemann (Saarbrücken, DE); Sabrina Bleif (Staufen, CH); Michael Kleser (Völklingen, DE); Rita Bernhardt (Saarbrücken, DE)
Assignee: SANOFI CHIMIE
C12P33/16C12N9/0081C12N9/0095C12N9/1029C12P7/625C12P33/00C12Y114/15006C12Y203/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,308,972
App. No.
14/898,655
Granted
Jun 4, 2019
Kind
B2
Abstract

The subject of the present invention is a whole-cell catalysis process for converting substrates of cytochrome P450 monooxygenases of eukaryotic origin into valuable biotechnological products. The subject of the present invention is also microorganisms genetically engineered to achieve those biotransformations with high rates and processes to prepare these microorganism strains.

Claims (25)

1. A genetically engineered microorganism capable of converting cholesterol, cholesterol analogs, and derivatives thereof into steroid hormones precursors,

wherein said microorganism comprises at least one DNA sequence encoding a cytochrome P450 of eukaryotic origin, an exogenous DNA sequence encoding Adx, and an exogenous DNA sequence encoding AdR,

wherein said microorganism is Bacillus megaterium,

wherein said cytochrome P450 of eukaryotic origin is selected from the group consisting of CYP11A1, CYP17A1, CYP11B1, CYP11B2, CYP3A4, CYP46A1, CYP27A1, CYP21A1, and CYP21A2, and

wherein the gene PhaC is overexpressed by introducing into said microorganism an exogenous DNA sequence encoding PhaC.

2. The genetically engineered microorganism according to claim 1 , wherein said exogenous DNA sequences have been introduced into said microorganism by means of genetic engineering techniques.

3. The genetically engineered microorganism according to claim 2 , wherein said microorganism has been transformed with at least one plasmid comprising said exogenous DNA sequences.

4. The genetically engineered microorganism according to claim 1 , wherein said exogenous DNA sequences are integrated into the genome of said microorganism.

5. The genetically engineered microorganism according to claim 1 , wherein said microorganism further comprises a functional endogenous polymerase system capable of building polyhydroxyalkanoate bodies.

6. The genetically engineered microorganism according to claim 1 , wherein said microorganism is Bacillus megaterium MS941 strain.

7. A method for producing steroid hormones precursors, comprising the steps of:

a. Providing a microorganism according to claim 1 ,

b. Culturing said microorganism under conditions allowing the expression of said exogenous DNA sequences,

c. Contacting said microorganism culture with a substrate selected from the group consisting of cholesterol, cholesterol analogs, and derivatives thereof, and

d. Recovering steroid hormones precursors.

8. The method according to claim 7 , wherein:

a. said substrate is selected from the group consisting of cholesterol, campesterol, ergostadienol, desmosterol, beta-sitosterol, generol and a mixture of oxysterols, and

b. said steroid hormones precursor is pregnenolone.

9. The method according to claim 7 , wherein said substrate is solubilized into β-cyclodextrin and saponin.

10. A method of preparing a genetically engineered microorganism according to claim 1 capable of converting cholesterol, cholesterol analogs, and derivatives thereof into steroid hormones precursors, comprising the steps of:

a. Providing a microorganism, wherein said microorganism is Bacillus megaterium ; and

b. Introducing by means of genetic engineering techniques into said microorganism at least one DNA sequence encoding a cytochrome P450 of eukaryotic origin, an exogenous DNA sequence encoding Adx, an exogenous DNA sequence encoding AdR, and an exogenous DNA sequence encoding PhaC, to overexpress gene PhaC,

wherein said cytochrome P450 of eukaryotic origin is selected from the group consisting of CYP11A1, CYP17A1, CYP11B1, CYP11B2, CYP3A4, CYP46A1, CYP27A1, CYP21A1, and CYP21A2.

11. The method according to claim 10 , wherein said microorganism comprises a functional endogenous polymerase system capable of building polyhydroxyalkanoate bodies.

12. The method according to claim 10 , wherein said microorganism is Bacillus megaterium MS941 strain.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2023
From: SANOFI
To: EUROAPI FRANCE
Reel/Frame 065978/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2016
From: BERNHARDT, RITA; BLEIF, SABRINA; GERBER, ADRIAN; HANNEMANN, FRANK; KLESER, MICHAEL
To: SANOFI CHIMIE
Reel/Frame 037655/0234 →
Priority Claims (1)
EP 13305814 · Jun 17, 2013 · regional
Continuity (1)
Related Publication 20160376625A1 · Dec 29, 2016